R&D Spending Showdown: Gilead Sciences, Inc. vs Dr. Reddy's Laboratories Limited

Pharma Giants' R&D Spending: A Decade of Divergence

__timestampDr. Reddy's Laboratories LimitedGilead Sciences, Inc.
Wednesday, January 1, 2014124020000002854000000
Thursday, January 1, 2015174490000003014000000
Friday, January 1, 2016178340000005098000000
Sunday, January 1, 2017195510000003734000000
Monday, January 1, 2018182650000005018000000
Tuesday, January 1, 2019156070000009106000000
Wednesday, January 1, 2020154100000005039000000
Friday, January 1, 2021165410000005363000000
Saturday, January 1, 2022174820000004977000000
Sunday, January 1, 2023193810000006923000000
Monday, January 1, 2024228730000005907000000
Loading chart...

Unleashing insights

R&D Spending Trends: A Tale of Two Giants

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Gilead Sciences, Inc. and Dr. Reddy's Laboratories Limited have showcased contrasting strategies in their R&D investments. From 2014 to 2023, Dr. Reddy's Laboratories consistently outpaced Gilead, with R&D expenses peaking at an impressive 22.9 billion in 2024. This represents a growth of approximately 84% from their 2014 spending. In contrast, Gilead's R&D expenditure saw a more modest increase, with a notable peak in 2019 at 9.1 billion, before stabilizing around 6.9 billion in 2023. The data suggests that while Dr. Reddy's is aggressively investing in innovation, Gilead is taking a more measured approach. Missing data for Gilead in 2024 leaves room for speculation on their future strategy. As the pharmaceutical landscape evolves, these spending patterns will be crucial in shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025